Classic steroids such as Dianabol, Trenbolone, Testosterone, and Deca Durabolin became mainstays in strength sports and ...

Reducing the number of shares that will be added to the Company’s outstanding shares from ~300,000 to between ~130,000-150,000 (subject to the share price upon warrant exercise). This amendment ...

Fulcrum granted the new employee 130,000 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as ...

Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" ...

The Notice has no immediate effect on the listing or trading of the Company’s common shares. The Company intends to monitor the bid price of its common shares and consider available options to regain ...

Annette Slyman, Chief Operating Officer, Life Backup Plan by Galacxia, Inc ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 ...

This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational ...

In the publication, the authors describe the long-term properties of a human stem-cell derived GABAergic interneuron cell therapy, the clinical-grade version of which, called NRTX-1001, is currently ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ...

Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months vs. 11.8 months for antibody drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single agent ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clini ...